QR kód

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

Background: The current clinical practice for patients affected by Non-Small Cell Lung Cancer (NSCLC) with uncommon mutation is based on afatinib and osimertinib, second and third generation of Tyrosine Kinase Inhibitor (TKI) respectively. For uncommon EGFR mutations, it is still unclear which EGFR...

Celý popis

Uloženo v:
Hlavní autoři: Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia
Médium: Artigo
Jazyk:Inglês
Vydáno: AboutScience Srl 2022-01-01
Edice:Global & Regional Health Technology Assessment
Témata:
Afatinib
Budget Impact
NSCLC
Osimertinib
Uncommon mutation
On-line přístup:https://journals.aboutscience.eu/index.php/grhta/article/view/2351
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky